About McKesson Corporation
https://www.mckesson.comMcKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S.
CEO
Brian S. Tyler
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1998-01-05 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 809
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:12.03M
Value:$10.04B
BLACKROCK INC.
Shares:11.47M
Value:$9.57B
BLACKROCK, INC.
Shares:11.3M
Value:$9.42B
Summary
Showing Top 3 of 2,337
About McKesson Corporation
https://www.mckesson.comMcKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $103.15B ▲ | $2.07B ▼ | $1.11B ▲ | 1.08% ▲ | $8.95 ▲ | $1.47B ▲ |
| Q1-2026 | $97.83B ▲ | $2.24B ▲ | $784M ▼ | 0.8% ▼ | $6.28 ▼ | $1.26B ▼ |
| Q4-2025 | $90.82B ▼ | $1.88B ▼ | $1.26B ▲ | 1.39% ▲ | $10.06 ▲ | $1.71B ▲ |
| Q3-2025 | $95.29B ▲ | $1.93B ▼ | $879M ▲ | 0.92% ▲ | $6.98 ▲ | $1.45B ▲ |
| Q2-2025 | $93.65B | $2.4B | $241M | 0.26% | $1.87 | $775M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $4.11B ▲ | $84.16B ▲ | $84.74B ▲ | $-1.74B ▲ |
| Q1-2026 | $2.42B ▼ | $81.31B ▲ | $82.17B ▲ | $-1.97B ▲ |
| Q4-2025 | $5.69B ▲ | $75.14B ▲ | $76.83B ▲ | $-2.07B ▲ |
| Q3-2025 | $1.13B ▼ | $71.08B ▼ | $73.78B ▼ | $-3.08B ▼ |
| Q2-2025 | $2.51B | $72.43B | $75.07B | $-3.02B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $1.21B ▲ | $2.42B ▲ | $-24M ▲ | $-961M ▼ | $1.43B ▲ | $2.53B ▲ |
| Q1-2026 | $784M ▼ | $-918M ▼ | $-3.56B ▼ | $1.18B ▲ | $-3.27B ▼ | $-1.03B ▼ |
| Q4-2025 | $1.31B ▲ | $7.75B ▲ | $-224M ▼ | $-2.85B ▼ | $4.67B ▲ | $7.47B ▲ |
| Q3-2025 | $928M ▲ | $-2.38B ▼ | $-136M ▲ | $1.3B ▲ | $-1.23B ▼ | $-2.58B ▼ |
| Q2-2025 | $287M | $2.1B | $-286M | $-1.6B | $207M | $1.88B |
Revenue by Products
| Product | Q3-2025 | Q4-2025 | Q2-2026 | Q1-2026 |
|---|---|---|---|---|
 International Segment | $3.86Bn ▲ | $3.46Bn ▼ | $0 ▼ | $3.74Bn ▲ |
 MedicalSurgical Solutions Segment | $2.95Bn ▲ | $2.85Bn ▼ | $2.95Bn ▲ | $2.70Bn ▼ |
 Prescription Technology Solutions | $1.37Bn ▲ | $1.34Bn ▼ | $1.38Bn ▲ | $1.43Bn ▲ |
 US Pharmaceutical Segment | $87.11Bn ▲ | $83.17Bn ▼ | $0 ▼ | $89.95Bn ▲ |
Revenue by Geography
| Region | Q3-2020 | Q2-2020 | Q4-2020 | Q1-2021 |
|---|---|---|---|---|
 International Segment | $9.86Bn ▲ | $9.32Bn ▼ | $9.75Bn ▲ | $8.55Bn ▼ |
 UNITED STATES | $49.31Bn ▲ | $48.29Bn ▼ | $48.79Bn ▲ | $47.13Bn ▼ |
CEO
Brian S. Tyler
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1998-01-05 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 809
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:12.03M
Value:$10.04B
BLACKROCK INC.
Shares:11.47M
Value:$9.57B
BLACKROCK, INC.
Shares:11.3M
Value:$9.42B
Summary
Showing Top 3 of 2,337